These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12511437)

  • 41. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study.
    Nickel JC; Herschorn S; Whitmore KE; Forrest JB; Hu P; Friedman AJ; Baseman AS
    J Urol; 2015 Mar; 193(3):857-62. PubMed ID: 25245489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Interstitial cystitis--cyclosporin A has better outcome than pentosan polysulfate sodium].
    Witte F
    Aktuelle Urol; 2007 Jan; 38(1):4-6. PubMed ID: 17290324
    [No Abstract]   [Full Text] [Related]  

  • 43. A preliminary study of chitosan-pentosan polysulfate sodium complex as vaginal sustained drug delivery system in a rare disease treatment.
    Raspagni A; Perugini P; Porru D; Pavanetto F
    J Control Release; 2010 Nov; 148(1):e118-9. PubMed ID: 21529589
    [No Abstract]   [Full Text] [Related]  

  • 44. [Juvenile onset Creutzfeldt-Jakob disease with the history of neurosurgical operation].
    Sato M; Murahashi M; Hara H; Jimi T; Wakayama Y
    Rinsho Shinkeigaku; 2000 May; 40(5):428-32. PubMed ID: 11002723
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of pentosan polysulphate and heparin. II: Effects of subcutaneous injection.
    Fischer AM; Merton RE; Marsh NA; Williams S; Gaffney PJ; Barrowcliffe TW; Thomas DP
    Thromb Haemost; 1982 Apr; 47(2):109-13. PubMed ID: 6179183
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quinacrine in possible or probable CJD: if you had suspected CJD would you be indifferent between placebo and quinacrine?
    Braunholtz D; Harris J
    BMJ; 2002 Jan; 324(7331):239. PubMed ID: 11809660
    [No Abstract]   [Full Text] [Related]  

  • 47. Fast-track CJD trial: two years late, but not derailed.
    Lancet Neurol; 2004 May; 3(5):257. PubMed ID: 15099535
    [No Abstract]   [Full Text] [Related]  

  • 48. In search of a cure for CJD.
    Thompson C
    Nature; 2001 Feb; 409(6821):660-1. PubMed ID: 11217834
    [No Abstract]   [Full Text] [Related]  

  • 49. Rapid drug trial offers hope to CJD patients.
    Giles J
    Nature; 2003 Dec; 426(6966):487. PubMed ID: 14654808
    [No Abstract]   [Full Text] [Related]  

  • 50. How safe is paediatric tonsillectomy?
    Brown PM
    Int J Pediatr Otorhinolaryngol; 2006 Apr; 70(4):575-7. PubMed ID: 16442640
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of pentosan polysulphate (SP54) on the fibrinolytic enzyme system. An experimental animal study.
    Marsh NA; Gaffney PJ
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):255-61. PubMed ID: 2427408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Collyrex collyrium in patients wearing soft lenses].
    Caissial C; Chanteclair G; Reny A
    Bull Soc Ophtalmol Fr; 1983 Feb; 83(2):213-6. PubMed ID: 6193899
    [No Abstract]   [Full Text] [Related]  

  • 53. Drugs for malaria and psychosis may offer hope to people with CJD.
    Josefson D
    BMJ; 2001 Aug; 323(7310):416. PubMed ID: 11520828
    [No Abstract]   [Full Text] [Related]  

  • 54. Creutzfeldt-Jakob disease in Ireland: epidemiological aspects 1980-2002.
    Horan G; Keohane C; Molloy S; Howley R; Harney M; Heffernan J; McGuigan C; Hutchinson M; Brett F; Farrell M
    Eur Neurol; 2004; 51(3):132-7. PubMed ID: 14988606
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Haïk S; Marcon G; Mallet A; Tettamanti M; Welaratne A; Giaccone G; Azimi S; Pietrini V; Fabreguettes JR; Imperiale D; Cesaro P; Buffa C; Aucan C; Lucca U; Peckeu L; Suardi S; Tranchant C; Zerr I; Houillier C; Redaelli V; Vespignani H; Campanella A; Sellal F; Krasnianski A; Seilhean D; Heinemann U; Sedel F; Canovi M; Gobbi M; Di Fede G; Laplanche JL; Pocchiari M; Salmona M; Forloni G; Brandel JP; Tagliavini F
    Lancet Neurol; 2014 Feb; 13(2):150-8. PubMed ID: 24411709
    [TBL] [Abstract][Full Text] [Related]  

  • 56. U.K. science. Industry-academic drug screening plan targets CJD.
    Marshall E
    Science; 2005 Apr; 308(5721):477. PubMed ID: 15845809
    [No Abstract]   [Full Text] [Related]  

  • 57. Perioperative Management of Patients Receiving Pentosan Polysulfate Sodium (Elmiron).
    Narouze S; Provenzano D; Rech GR
    Reg Anesth Pain Med; 2016; 41(5):658. PubMed ID: 27547908
    [No Abstract]   [Full Text] [Related]  

  • 58. Altering the course of proliferative nephritides: the challenge of the 1990s.
    Wardle EN
    J Int Med Res; 1992 Sep; 20(5):361-70. PubMed ID: 1280605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Determinations of clinical variations and lipid metabolism in patients with chronic ischemia of the lower extremities by means of a pentosan sulfonic ester and xanthinol niacinate combination].
    González González M; Azcona Elizalde JM; Lorente Navarro MC; Duato Jane A
    Angiologia; 1979; 31(4):180-4. PubMed ID: 382919
    [No Abstract]   [Full Text] [Related]  

  • 60. Quinacrine in possible or probable CJD: it is blinded investigators, not patients, who must be in equipoise over treatment.
    Cooper E
    BMJ; 2002 Jan; 324(7331):239. PubMed ID: 11831208
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.